For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
REGULATORY
Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
The 150-day regular session of Japan’s Diet came to a close on June 21. The Ministry of Health, Labor and Welfare (MHLW) saw all its seven bills enacted, including legislation to establish a so-called Japanese version of the US Centers…
To read the full story
Related Article
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
- MHLW Holds 1st Meeting to Consider Structure of Japan CDC
January 26, 2024
- MHLW Preparatory Council Boots Up for Japan-Version of CDC
October 13, 2023
- Japan Diet Clears Lawmaker-Sponsored Dementia Bill
June 15, 2023
- Japan Diet Enacts Genomic Medicine Promotion Bill
June 12, 2023
- Japan Diet Enacts Bill to Create “Japan CDC”
June 1, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Lower House Clears Bill to Amend Next-Gen Medical Infrastructure Law
April 14, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- “Pseudonymized Medical Info” to Be Created to Fuel Healthcare Data Use in Filing
January 5, 2023
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
REGULATORY
- MHLW Issues Guidance on Early Approval Scheme for MCMs
November 8, 2024
- Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
- Chuikyo Doubts Effect of Re-Pricing for Unprofitable Products
November 7, 2024
- Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
- PMDA Opens US Office in Washington, D.C.
November 5, 2024
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…